Lenalidomide maintenance in high risk chronic lymphocytic leukaemia: practice changing study or hypothesis generating approach?
Mené sur 89 patients atteints d'une leucémie lymphoïde chronique à haut risque, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du lénalidomide en traitement d'entretien après une chimio-immunothérapie de première ligne
Only 5 years ago, when Anna Maria Fink and colleagues' study1 started recruiting patients, lenalidomide was judged as a drug that was worthwhile further exploring in chronic lymphocytic leukaemia as a potential practice changing new agent. Nowadays, the fast pace of drug development in chronic lymphocytic leukaemia has dropped lenalidomide out of the group of newer compounds. Due to the rapid advances in therapeutics for chronic lymphocytic leukaemia leading to the approval of a new class of highly effective and tolerated agents, including kinase inhibitors and BCL2 inhibitors, the results of this study are unlikely to affect the current clinical practice.
The Lancet Haematology , commentaire, 2016